Single-step nanoplasmonic VEGF 165 aptasensor for early cancer diagnosis

Hansang Cho, Erh Chia Yeh, Raghu Sinha, Ted A. Laurence, Jane P. Bearinger, Luke P. Lee

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Early cancer diagnosis is very important for the prevention or mitigation of metastasis. However, effective and efficient methods are needed to improve the diagnosis and assessment of cancer. Here, we report a single-step detection method using a nanoplasmonic aptamer sensor (aptasensor), targeting a vascular endothelial growth factor-165 (VEGF 165), a predominant biomarker of cancer angiogenesis. Our single-step detection is accomplished by (1) specific target recognition by an aptamer-target molecule interaction and (2) direct readouts of the target recognition. The readout is achieved by inactivation of surface plasmon enhancement of fluorescent probes preattached to the aptamers. Our aptasensor provides the appropriate sensitivity for clinical diagnostics with a wide range of linear detection from 25 pg/mL to 25 μg/mL (=from 1.25 pM to 1.25 μM), high specificity for VEGF 165 against PDGF-BB, osteopontin (OPN), VEGF 121, NaCl, and temporal/thermal/biological stability. In experiments with 100% serum and saliva from clinical samples, readouts of the aptasensor and an ELISA for VEGF 165 show good agreement within the limit of the ELISA kit. We envision that our developed aptasensor holds utilities for point-of-care cancer prognostics by incorporating simplicity in detection, low-cost for test, and required small sample volumes.

Original languageEnglish (US)
Pages (from-to)7607-7614
Number of pages8
JournalACS Nano
Volume6
Issue number9
DOIs
StatePublished - Sep 25 2012

Fingerprint

cancer
readout
target recognition
sensors
Sensors
saliva
angiogenesis
Osteopontin
kits
biomarkers
metastasis
Biomarkers
Tumor Biomarkers
Fluorescent Dyes
serums
deactivation
Vascular Endothelial Growth Factor A
Molecules
human VEGFA protein
Intercellular Signaling Peptides and Proteins

All Science Journal Classification (ASJC) codes

  • Materials Science(all)
  • Engineering(all)
  • Physics and Astronomy(all)

Cite this

Cho, H., Yeh, E. C., Sinha, R., Laurence, T. A., Bearinger, J. P., & Lee, L. P. (2012). Single-step nanoplasmonic VEGF 165 aptasensor for early cancer diagnosis. ACS Nano, 6(9), 7607-7614. https://doi.org/10.1021/nn203833d
Cho, Hansang ; Yeh, Erh Chia ; Sinha, Raghu ; Laurence, Ted A. ; Bearinger, Jane P. ; Lee, Luke P. / Single-step nanoplasmonic VEGF 165 aptasensor for early cancer diagnosis. In: ACS Nano. 2012 ; Vol. 6, No. 9. pp. 7607-7614.
@article{21edaec3937242808ca6d620456f854e,
title = "Single-step nanoplasmonic VEGF 165 aptasensor for early cancer diagnosis",
abstract = "Early cancer diagnosis is very important for the prevention or mitigation of metastasis. However, effective and efficient methods are needed to improve the diagnosis and assessment of cancer. Here, we report a single-step detection method using a nanoplasmonic aptamer sensor (aptasensor), targeting a vascular endothelial growth factor-165 (VEGF 165), a predominant biomarker of cancer angiogenesis. Our single-step detection is accomplished by (1) specific target recognition by an aptamer-target molecule interaction and (2) direct readouts of the target recognition. The readout is achieved by inactivation of surface plasmon enhancement of fluorescent probes preattached to the aptamers. Our aptasensor provides the appropriate sensitivity for clinical diagnostics with a wide range of linear detection from 25 pg/mL to 25 μg/mL (=from 1.25 pM to 1.25 μM), high specificity for VEGF 165 against PDGF-BB, osteopontin (OPN), VEGF 121, NaCl, and temporal/thermal/biological stability. In experiments with 100{\%} serum and saliva from clinical samples, readouts of the aptasensor and an ELISA for VEGF 165 show good agreement within the limit of the ELISA kit. We envision that our developed aptasensor holds utilities for point-of-care cancer prognostics by incorporating simplicity in detection, low-cost for test, and required small sample volumes.",
author = "Hansang Cho and Yeh, {Erh Chia} and Raghu Sinha and Laurence, {Ted A.} and Bearinger, {Jane P.} and Lee, {Luke P.}",
year = "2012",
month = "9",
day = "25",
doi = "10.1021/nn203833d",
language = "English (US)",
volume = "6",
pages = "7607--7614",
journal = "ACS Nano",
issn = "1936-0851",
publisher = "American Chemical Society",
number = "9",

}

Cho, H, Yeh, EC, Sinha, R, Laurence, TA, Bearinger, JP & Lee, LP 2012, 'Single-step nanoplasmonic VEGF 165 aptasensor for early cancer diagnosis', ACS Nano, vol. 6, no. 9, pp. 7607-7614. https://doi.org/10.1021/nn203833d

Single-step nanoplasmonic VEGF 165 aptasensor for early cancer diagnosis. / Cho, Hansang; Yeh, Erh Chia; Sinha, Raghu; Laurence, Ted A.; Bearinger, Jane P.; Lee, Luke P.

In: ACS Nano, Vol. 6, No. 9, 25.09.2012, p. 7607-7614.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Single-step nanoplasmonic VEGF 165 aptasensor for early cancer diagnosis

AU - Cho, Hansang

AU - Yeh, Erh Chia

AU - Sinha, Raghu

AU - Laurence, Ted A.

AU - Bearinger, Jane P.

AU - Lee, Luke P.

PY - 2012/9/25

Y1 - 2012/9/25

N2 - Early cancer diagnosis is very important for the prevention or mitigation of metastasis. However, effective and efficient methods are needed to improve the diagnosis and assessment of cancer. Here, we report a single-step detection method using a nanoplasmonic aptamer sensor (aptasensor), targeting a vascular endothelial growth factor-165 (VEGF 165), a predominant biomarker of cancer angiogenesis. Our single-step detection is accomplished by (1) specific target recognition by an aptamer-target molecule interaction and (2) direct readouts of the target recognition. The readout is achieved by inactivation of surface plasmon enhancement of fluorescent probes preattached to the aptamers. Our aptasensor provides the appropriate sensitivity for clinical diagnostics with a wide range of linear detection from 25 pg/mL to 25 μg/mL (=from 1.25 pM to 1.25 μM), high specificity for VEGF 165 against PDGF-BB, osteopontin (OPN), VEGF 121, NaCl, and temporal/thermal/biological stability. In experiments with 100% serum and saliva from clinical samples, readouts of the aptasensor and an ELISA for VEGF 165 show good agreement within the limit of the ELISA kit. We envision that our developed aptasensor holds utilities for point-of-care cancer prognostics by incorporating simplicity in detection, low-cost for test, and required small sample volumes.

AB - Early cancer diagnosis is very important for the prevention or mitigation of metastasis. However, effective and efficient methods are needed to improve the diagnosis and assessment of cancer. Here, we report a single-step detection method using a nanoplasmonic aptamer sensor (aptasensor), targeting a vascular endothelial growth factor-165 (VEGF 165), a predominant biomarker of cancer angiogenesis. Our single-step detection is accomplished by (1) specific target recognition by an aptamer-target molecule interaction and (2) direct readouts of the target recognition. The readout is achieved by inactivation of surface plasmon enhancement of fluorescent probes preattached to the aptamers. Our aptasensor provides the appropriate sensitivity for clinical diagnostics with a wide range of linear detection from 25 pg/mL to 25 μg/mL (=from 1.25 pM to 1.25 μM), high specificity for VEGF 165 against PDGF-BB, osteopontin (OPN), VEGF 121, NaCl, and temporal/thermal/biological stability. In experiments with 100% serum and saliva from clinical samples, readouts of the aptasensor and an ELISA for VEGF 165 show good agreement within the limit of the ELISA kit. We envision that our developed aptasensor holds utilities for point-of-care cancer prognostics by incorporating simplicity in detection, low-cost for test, and required small sample volumes.

UR - http://www.scopus.com/inward/record.url?scp=84866704799&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866704799&partnerID=8YFLogxK

U2 - 10.1021/nn203833d

DO - 10.1021/nn203833d

M3 - Article

VL - 6

SP - 7607

EP - 7614

JO - ACS Nano

JF - ACS Nano

SN - 1936-0851

IS - 9

ER -

Cho H, Yeh EC, Sinha R, Laurence TA, Bearinger JP, Lee LP. Single-step nanoplasmonic VEGF 165 aptasensor for early cancer diagnosis. ACS Nano. 2012 Sep 25;6(9):7607-7614. https://doi.org/10.1021/nn203833d